Business
Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product
Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product.
About this update from Itonis, Inc.
[{"type":"text","content":"\n \n \n Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product\n \n \nItonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product\n \n LAGUNA HILLS, CA--(Marketwired - Jun 2, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl® over-the-counter homeopathic product for nausea relief. \n In addition, the Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office for its Emesyl® trademark.\n The NDC number and trademark Notice of Allowance has enabled the Company to enter the final stage of its product packaging design, and the production of Emesyl® will soon begin with its manufacturer, Oasis Health Products.\n The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues.\n \"Reaching these significant NDC and trademark milestones required a lot of hard work and patience. We have wasted no time in prompting our manufacturer to finalize all steps for the first production run of Emesyl®, bringing us one step closer to market,\" said Dr. Charles H. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.\n The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company. (http://pharma.about.com/od/Over-the-Counter-Medicine/a/The-Over-the-counter-Drug-Industry.htm)\n In another development, the Company's research team received its 30 day testing feedback on its Cloud9 Project and the ITNS management team has decided to terminate the project in the interest of shareholder value. The Company, however, is moving forward...